TLR2 is constitutively expressed within the kidney and participates in ischemic renal injury through both myD88-dependent and -independent pathways

Journal of Immunology

Volumn 178, Issue 10, 2007, Pages 6252-6258

  Shigeoka, Alana A ^a   Holscher, Todd D ^a   King, Andrew J ^b   Hall, Frank W ^c   Kiosses, William B ^a   Tobias, Peter S ^a   Mackman, Nigel ^a   McKay, Dianne B ^a,b  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

^b Green Hospital   (United States)

^c SCRIPPS CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MYELOID DIFFERENTIATION FACTOR 88; TOLL LIKE RECEPTOR 2;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CELL TYPE; CONTROLLED STUDY; KIDNEY ISCHEMIA; KIDNEY TUBULE; MALE; MOUSE; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; TISSUE SECTION; WILD TYPE;

EID: 34248140689     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.178.10.6252     Document Type: Article

References (48)

1. Akira, S., and K. Takeda. 2004. Toll-like receptor signalling. Nat. Rev. Immunol. 4: 499-511.
2. Hoebe, K., E. M. Janssen, S. O. Kim, L. Alexopoulou, R. A. Flavell, J. Han, and B. Beutler. 2003. Up-regulation of costimulatory molecules induced by lipopolysaccharide and double-stranded RNA occurs by Trif-dependent and Trif-independent pathways. Nat. Immunol. 4: 1223-1229.
3. Beutler, B., and J. Hoffmann. 2004. Innate immunity. Curr. Opin. Immunol. 16: 1-3.
4. Matzinger, P. 2002. The danger model: a renewed sense of self. Science 296: 301-305.
5. Aliprantis, A. O., R. B. Yang, M. R. Mark, S. Suggett, B. Devaux, J. D. Radolf, G. R. Klimpel, P. Godowski, and A. Zychlinsky. 1999. Cell activation and apoptosis by bacterial lipoproteins through Toll-like receptor-2. Science 285: 736-739.
6. Aliprantis, A. O., R. B. Yang, D. S. Weiss, P. Godowski, and A. Zychlinsky. 2000. The apoptotic signaling pathway activated by Toll-like receptor-2. EMBO J. 19: 3325-3336.
7. Shi, Y., J. E. Evans, and K. L. Rock. 2003. Molecular identification of a danger signal that alerts the immune system to dying cells. Nature 425: 516-521.
8. Tokunaga, T., H. Yamamoto, S. Shimada, H. Abe, T. Fukuda, Y. Fujisawa, Y. Furutani, O. Yano, T. Kataoka, T. Sudo, et al. 1984. Antitumor activity of deoxyribonucleic acid fraction from Mycobacterium bovis BCG. I. Isolation, physicochemical characterization, and antitumor activity. J. Natl. Cancer Inst. 72: 955-962.
9. Ishii, K. J., and S. Akira. 2005. Innate immune recognition of nucleic acids: beyond Toll-like receptors. Int. J. Cancer 117: 517-523.
10. Powell, J. D., and M. R. Horton. 2005. Threat matrix: low-molecular-weight hyaluronan (HA) as a danger signal. Immunol. Res. 31: 207-218.
11. Smiley, S. T., J. A. King, and W. W. Hancock. 2001. Fibrinogen stimulates macrophage chemokine secretion through Toll-like receptor 4. J. Immunol. 167: 2887-2894.
12. DeMarco, R. A., M. P. Fink, and M. T. Lotze. 2005. Monocytes promote natural killer cell interferon γ production in response to the endogenous danger signal HMGB1. Mol. Immunol. 42: 433-444.
13. Millar, D. G., K. M. Garza, B. Odermatt, A. R. Elford, N. Ono, Z. Li, and P. S. Ohashi. 2003. Hsp70 promotes antigen-presenting cell function and converts T-cell tolerance to autoimmunity in vivo. Nat. Med. 9: 1469-1476.
14. Strbo, N., S. Oizumi, V. Sotosek-Tokmadzic, and E. R. Podack. 2003. Perforin is required for innate and adaptive immunity induced by heat shock protein gp96. Immunity 18: 381-390.
15. Shen, X. D., B. Ke, Y. Zhai, F. Gao, R. W. Busuttil, G. Cheng, and J. W. Kupiec-Weglinski. 2005. Toll-like receptor and heme oxygenase-1 signaling in hepatic ischemia/reperfusion injury. Am. J. Transplant. 5: 1793-1800.
16. Ojaniemi, M., M. Liljeroos, K. Harju, R. Sormunen, R. Vuolteenaho, and M. Hallman. 2006. TLR-2 is up-regulated and mobilized to the hepatocyte plasma membrane in the space of Disse and to the Kupffer cells TLR-4 dependently during acute endotoxemia in mice. Immunol. Lett. 102: 158-168.
17. Xiong, J., Z. H. Zhu, J. S. Liu, Y. Wang, and H. S. Wu. 2006. The expression of Toll-like receptor 2, 4 of livers in mice with systemic inflammatory response syndrome. Hepatobiliary Pancreat. Dis. Int. 5: 143-146.
18. Li, C., T. Ha, J. Kelley, X. Gao, Y. Qiu, R. L. Kao, W. Browder, and D. L. Williams. 2004. Modulating Toll-like receptor mediated signaling by (1→3)-β-D-glucan rapidly induces cardioprotection. Cardiovasc. Res. 61: 538-547.
19. Hua, F., T. Ha, J. Ma, X. Gao, J. Kelley, D. L. Williams, I. W. Browder, R. L. Kao, and C. Li. 2005. Blocking the MyD88-dependent pathway protects the myocardium from ischemia/reperfusion injury in rat hearts. Biochem. Biophys. Res. Commun. 338: 1118-1125.
20. O'Neill, L. A. 2005. TLRs play good cop, bad cop in the lung. Nat. Med. 11: 1161-1162.
21. Ritter, M., D. Mennerich, A. Weith, and P. Seither. 2005. Characterization of Toll-like receptors in primary lung epithelial cells: strong impact of the TLR3 ligand poly(I:C) on the regulation of Toll-like receptors, adaptor proteins and inflammatory response. J. Inflamm. 2: 16.
22. Maslinska, D., M. Laure-Kamionowska, and S. Maslinski. 2004. Toll-like receptors in rat brains injured by hypoxic-ischaemia or exposed to staphylococcal α-toxin. Folia Neuropathol. 42: 125-132.
23. Vezzani, A. 2006. The Toll receptor family: from microbial recognition to seizures. Epilepsy Curr. 6: 11-13.
24. Frost, R. A., G. J. Nystrom, and C. H. Lang. 2006. Multiple Toll-like receptor ligands induce an IL-6 transcriptional response in skeletal myocytes. Am. J. Physiol. 290: R773-R784.
25. Schreiner, B., J. Voss, J. Wischhusen, Y. Dombrowski, A. Steinie, H. Lochmuller, M. Dalakas, A. Melms, and H. Wiendl. 2006. Expression of Toll-like receptors by human muscle cells in vitro and in vivo: TLR3 is highly expressed in inflammatory and HIV myopathies, mediates IL-8 release and upregulation of NKG2D-ligands. FASEB J. 20: 118-120.
26. Chabot, S., J. S. Wagner, S. Farrant, and M. R. Neutra. 2006. TLRs regulate the gatekeeping functions of the intestinal follicle-associated epithelium. J. Immunol. 176: 4275-4283.
27. Abreu, M. T., M. Fukata, and M. Arditi. 2005. TLR signaling in the gut in health and disease. J. Immunol. 174: 4453-4460.
28. Leemans, J. C., G. Stokman, N. Claessen, K. M. Rouschop, G. J. Teske, C. J. Kirschning, S. Akira, T. van der Poll, J. J. Weening, and S. Florquin. 2005. Renal-associated TLR2 mediates ischemia/reperfusion injury in the kidney. J. Clin. Invest. 115: 2894-2903.
29. Brown, H. J., H. R. Lock, S. H. Sacks, and M. G. Robson. 2006. TLR2 stimulation of intrinsic renal cells in the induction of immune-mediated glomerulonephritis. J. Immunol. 177: 1925-1931.
30. Wolfs, T. G., W. A. Buurman, A. van Schadewijk, B. de Vries, M. A. Daemen, P. S. Hiemstra, and C. van't Veer. 2002. In vivo expression of Toll-like receptor 2 and 4 by renal epithelial cells: IFN-γ and TNF-α mediated up-regulation during inflammation. J. Immunol. 168: 1286-1293.
31. Kim, B. S., S. W. Lim, C. Li, J. S. Kim, B. K. Sun, K. O. Ann, S. W. Han, J. Kim, and C. W. Yang. 2005. Ischemia-reperfusion injury activates innate immunity in rat kidneys. Transplantation 79: 1370-1377.
32. Bjorkbacka, H., K. A. Fitzgerald, F. Huet, X. Li, J. A. Gregory, M. A. Lee, C. M. Ordija, N. E. Dowley, D. T. Golenbock, and M. W. Freeman. 2004. The induction of macrophage gene expression by LPS predominantly utilizes Myd88-independent signaling cascades. Physiol. Genomics 19: 319-330.
33. Ruse, M., and U. G. Knaus. 2006. New players in TLR-mediated innate immunity: PI3K and small Rho GTPases. Immunol. Res. 34: 33-48.
34. Frank, R. D., G. Schabbauer, T. Holscher, Y. Sato, M. Tencati, R. Pawlinski, and N. Mackman. 2005. The synthetic pentasaccharide fondaparinux reduces coagulation, inflammation and neutrophil accumulation in kidney ischemia-reperfusion injury. J. Thromb. Haemost. 3: 531-540.
35. Thurman, J. M., D. Ljubanovic, C. L. Edelstein, G. S. Gilkeson, and V. M. Holers. 2003. Lack of functional alternative complement pathways ameliorates ischemic acute renal failure in mice. J. Immunol. 170: 1517-1523.
36. Molls, R. R., V. Savransky, M. Liu, S. Bevans, T. Mehta, R. M. Tuder, L. S. King, and H. Rabb. 2006. Keratinocyte-derived chemokine is an early biomarker of ischemic acute kidney injury. Am. J. Physiol. 290: F1187-F1193.
37. Safirstein, R., J. Megyesi, S. J. Saggi, P. M. Price, M. Poon, B. J. Rollins, and M. B. Taubman. 1991. Expression of cytokine-like genes JE and KC is increased during renal ischemia. Am. J. Physiol. 261: F1095-F1101.
38. Calandra, T., J. Gerain, D. Heumann, J. D. Baumgartner, and M. P. Glauser. 1991. High circulating levels of interleukin-6 in patients with septic shock: evolution during sepsis, prognostic value, and interplay with other cytokines: the Swiss-Dutch J5 Immunoglobulin Study Group. Am. J. Med. 91: 23-29.
39. Damas, P., D. Ledoux, M. Nys, Y. Vrindts, D. De Groote, P. Franchimont, and M. Lamy. 1992. Cytokine serum level during severe sepsis in human IL-6 as a marker of severity. Ann. Surg. 215: 356-362.
40. Patel, N. S., P. K. Chatterjee, R. Di Paola, E. Mazzon, D. Britti, A. De Sarro, S. Cuzzocrea, and C. Thiemermann. 2005. Endogenous interleukin-6 enhances the renal injury, dysfunction, and inflammation caused by ischemia/reperfusion. J. Pharmacol. Exp. Ther. 312: 1170-1178.
41. Kielar, M. L., R. John, M. Bennett, J. A. Richardson, J. M. Shelton, L. Chen, D. R. Jeyarajah, X. J. Zhou, H. Zhou, B. Chiquett, et al. 2005. Maladaptive role of IL-6 in ischemic acute renal failure. J. Am. Soc. Nephrol. 16: 3315-3325.
42. Daemen, M. A., C. van't Veer, T. G. Wolfs, and W. A. Buurman. 1999. Ischemia/ reperfusion-induced IFN-γ up-regulation: involvement of IL-12 and IL-18. J. Immunol. 162: 5506-5510.
43. Tsuboi, N., Y. Yoshikai, S. Matsuo, T. Kikuchi, K. Iwami, Y. Nagai, O. Takeuchi, S. Akira, and T. Matsuguchi. 2002. Roles of Toll-like receptors in C-C chemokine production by renal tubular epithelial cells. J. Immunol. 169: 2026-2033.
44. Saemann, M. D., T. Weichhart, M. Zeyda, G. Staffler, M. Schunn, K. M. Stuhlmeier, Y. Sobanov, T. M. Stulnig, S. Akira, A. von Gabain, et al. 2005. Tamm-Horsfall glycoprotein links innate immune cell activation with adaptive immunity via a Toll-like receptor-4-dependent mechanism. J. Clin. Invest. 115: 468-475.
45. Arbibe, L., J. P. Mira, N. Teusch, L. Kline, M. Guha, N. Mackman, P. J. Godowski, R. J. Ulevitch, and U. G. Knaus. 2000. Toll-like receptor 2-mediated NF-κB activation requires a Rac1-dependent pathway. Nat. Immunol. 1: 533-540.
46. Strassheim, D., K. Asehnoune, J. S. Park, J. Y. Kim, Q. He, D. Richter, K. Kuhn, S. Mitra, and E. Abraham. 2004. Phosphoinositide 3-kinase and Akt occupy central roles in inflammatory responses of Toll-like receptor 2-stimulated neutrophils. J. Immunol. 172: 5727-5733.
47. Teusch, N., E. Lombardo, J. Eddleston, and U. G. Knaus. 2004. The low molecular weight GTPase RhoA and atypical protein kinase Cζ are required for TLR2-mediated gene transcription. J. Immunol. 173: 507-514.
48. Cantley, L. C. 2002. The phosphoinositide 3-kinase pathway. Science 296: 1655-1657.